共 247 条
[1]
Araujo JC(2013)Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial Lancet Oncol 14 1307-1316
[2]
Trudel GC(2017)Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer J Clin Oncol 35 40-47
[3]
Saad F(2017)Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL Study Eur Urol 71 151-154
[4]
Armstrong AJ(2016)Orteronel switch maintenance therapy in metastatic castration resistant prostate cancer after first-line docetaxel: a multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08/11) Prostate 76 1519-1527
[5]
Yu EY(2017)Abiraterone or enzalutamide in advanced castration-resistant prostate cancer: an indirect comparison Prostate 77 639-646
[6]
Bellmunt J(2010)Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 765-781
[7]
Beer TM(2012)Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 983-992
[8]
Kwon ED(2013)Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer J Clin Oncol 31 1740-1747
[9]
Drake CG(2015)Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5 J Clin Oncol 33 723-731
[10]
Fizazi K(2015)A multilevel approach to network meta-analysis within a frequentist framework Contemp Clin Trials 42 51-59